Company News

ReflectionBio – By Patients, For Patients ^®

Company News

By Patients, For Patients™ — More than a Patent Win: A Testament to Patient-driven Resilience

19 June 2026 — Reflection Biotechnologies (ReflectionBio®) today announced the successful maintenance of its European Patent No. 3662066 (Application No. EP18842071.5) following opposition proceedings before the European Patent Office (EPO). Despite challenges brought by two opponents, ReflectionBio—represented by Fish & Richardson—secured amended claims that preserve patent protection for its AAV gene therapy vector for treating Bietti Crystalline Dystrophy (BCD).

Publication: Evaluating precision medicine approaches for gene therapy in patient-specific cellular models of Bietti crystalline dystrophy

Publication: An In-Depth Single-Gene Worldwide Carrier Frequency and Genetic Prevalence Analysis of CYP4V2 as the Cause of Bietti Crystalline Dystrophy

ReflectionBio joins forces with patient organization Invincible Vision ahead of World Rare Disease Day for Bietti’s Crystalline Dystrophy (BCD)

SAN FRANCISCO & HONG KONG–(BUSINESS WIRE)–Today, Invincible Vision and ReflectionBio^® are launching their inaugural awareness and fundraising campaign, BY PATIENTS, FOR PATIENTS ™, for Bietti’s Crystalline Dystrophy (BCD).

Rare Disease Patient CEO Joins “Orphan Drug Development Guidebook” Task Force

Richard Yang, Founder & CEO of ReflectionBio and a rare disease patient, was invited to join the newly formed “Orphan Drug Development Guidebook” Task Force of International Rare Diseases Research Consortium (IRDiRC).